FindTrial
Sign In

MELAVIRDINE MESYLATE: PHARMACOCINETIC, RANDOMIZED COMPARISON, OF PARALLEL GROUPS AND OPEN MARBETE OF SQV + 3TC + AZT + DLV TWO OR THREE DAILY TIMES VS SQV + 3TC + AZT + DLV IN THE TREATMENT OF HIV POSITIVE PATIENTS

MELAVIRDINE MESYLATE: PHARMACOCINETIC, RANDOMIZED COMPARISON, OF PARALLEL GROUPS AND OPEN MARBETE OF SQV + 3TC + AZT + DLV TWO OR THREE DAILY TIMES VS SQV + 3TC + AZT + DLV IN THE TREATMENT OF HIV POSITIVE PATIENTS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REPEC
Registry ID
PER-018-98
Enrollment
Unknown
Registered
1998-12-24
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

NA Type of group

Sponsors

PHARMACIA & UPJOHN INTERAMERICAN CORPORATION,
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: NA

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

MeasureTime frame
Outcome name:NA Measure:NA Timepoints:NA—

Secondary

MeasureTime frame
Outcome name:NA Measure:NA Timepoints:NA—

Outcome results

None listed

Source: REPEC (via WHO ICTRP)